0001754068 2026-03-13 2026-03-13 0001754068 1 2026-03-13 2026-03-13 0001754068 2 2026-03-13 2026-03-13 iso4217:USD pure shares S-8 S-8 EX-FILING FEES 0001754068 Kalaris Therapeutics, Inc. N/A false false S-8 Kalaris Therapeutics, Inc. Equity Common Stock, $0.0001 par value per share true 1145120 9.12 10443494.40 0.0001381 1442.25 Equity Common Stock, $0.0001 par value per share true 53161 9.12 484828.32 0.0001381 66.96 10928322.72 1509.21 0.00 1509.21 (1) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Consists of 1,145,120 additional shares issuable under the 2020 Stock Option and Grant Plan. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Market on March 12, 2026. (1) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Market on March 12, 2026. (4) Consists of 53,161 additional shares issuable under the 2020 Employee Stock Purchase Plan.